For the eighth consecutive year, AUA’s AQUA Registry has been approved, by CMS, as a Qualified Clinical Data Registry (QCDR). For the 2023 reporting year, the AQUA Registry will offer a total of 58 quality measures. This includes 7 Non-QPP, 29 QPP and 20 eCQM (electronic clinical quality) measures. The Registry will also offer 2 test measures (AQUA01 and AUA02), which are meant to be used for internal quality improvement purposes. Please note the test measures cannot be used for 2023 MIPS reporting.  

Additionally, the CMS-approved measures address conditions such as prostate cancer, benign prostatic hyperplasia (BPH), urinary stones, bladder cancer and urinary incontinence. The QCDR designation is critical to the success of the AQUA Registry’s efforts to support its participants in fulfilling the reporting requirements set forth by CMS.